COMP <GO>
QGEN vs IBRX // EV/EBITDA & P/E VALUATION
Qiagen N.V. (NYSE) VS. ImmunityBio Inc. (NASDAQ) • 15-METRIC TALLY: QGEN 10
— IBRX 3
■ METRIC PARITY
LAST: $50.22 (-0.24%) • MKT CAP: $10.35B
valuation
17.6x
LAST: $8.29 (-5.15%) • MKT CAP: $8.79B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QGEN VS. IBRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QGEN | IBRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.20% | 96.00% | -33.80 | IBRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.00% | -27.30% | +35.30 | QGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 17.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | -3.33% | +7.70 | QGEN | /fcf-yield <GO> |
| Operating Margin | 22.30% | -60.00% | +82.30 | QGEN | /operating-margins <GO> |
| Net Profit Margin | 20.30% | -60.00% | +80.30 | QGEN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 180.00% | -174.30 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.52% | 0.00% | +0.52 | QGEN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 0.45 | +3.09 | QGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 6/9 | +3.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 71.0 | 44.3 | +26.70 | QGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.05 | -0.10 | IBRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.7x | 29.0x | -6.30 | QGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.35B | $8.79B | $1.56B | QGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QGEN REV | IBRX REV | QGEN GROSS % | IBRX GROSS % | QGEN FCF | IBRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.09B | $113.3M | 62.2% | 99.3% | $453.3M | -$308.8M |
| FY 2024 | $1.98B | $14.7M | 48.9% | 100.0% | $506.4M | -$398.1M |
| FY 2023 | $1.97B | $622.0K | — | — | $371.0M | -$366.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QGEN // BETA 0.95
IBRX // BETA 1.05